HIV

Broad-spectrum HIV-targeting monoclonal antibodies may lead to a cure for HIV in the future.

Evidence-based treatment for depression and adherence counseling could boost HIV treatment.

Successful highly active antiretroviral therapy (HAART) has allowed the long-term effects of HIV infection and chronic medication toxicity to become the primary cause of death and disability. However, HIV-positive patients are at greater risk for cardiovascular disease and cancers due to excessive inflammation, and HAART does not eliminate HIV-related inflammation even if the patient adheres to treatment perfectly.

HIV compromises the immune system, making patients more susceptible to tuberculosis.

T cell subset may play a crucial role in the development of diabetes.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.

Coinfection with HIV plus a hepatitis B, C, or both, adds to the risk of non-Hodgkins lymphoma.

Top news of the day from across the health care landscape.

Mytesi is the only FDA approved treatment for noninfectious diarrhea in HIV positive patients.

Study highlights care strategies for HIV patients to address the differences in the disease among patients in different age groups.

Limited evidence connects HIV severity and highly active antiretroviral therapy (HAART) regimens.

HIV-positive patients experience sudden death more often than the general population, but scant evidence connects HIV severity and highly active antiretroviral therapy regimens.

Large proportion of adolescents who are HIV-positive are unaware of their infection.

Adolescents underestimate their risk of contracting HIV, and 60% of infected patients are unaware of their status.

HIV-infected patients may have worse outcomes in ocular syphilis than those without the virus.

Researchers discover which type of gut bacteria may influence the effectiveness of chemotherapy.

Laquinimod provides hope for inhibiting aggressive multiple sclerosis.

The number of syphilis cases has risen steadily in the United States since 2000. Those who are at particularly elevated risk include men who have sex with men and patients infected with human immunodeficiency virus (HIV).

Generic abacavir and lamivudine (Epzicom) tablets are indicated for the treatment of HIV-1 infection in combination with other antiretroviral medicines.

Enzyme found to promote immune suppression by blocking the activation of anti-tumor T cells.

Teva has launched the generic equivalent of abacavir and lamivudine (Epzicom) tablets in the United States.

Funding of $24 million will support programs and studies that address HIV-infection and prevention among at-risk groups.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed effective techniques to boost HIV drug adherence.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed the importance of persistence in Truvada use for HIV pre-exposure prophylaxis.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed hurdles to proper drug adherence in HIV treatment.

Researchers create a treatment approach that singles out HIV reservoirs.

Clinicians may prefer venipuncture if multiple fingersticks are necessary.

HIV and tuberculosis (TB) have both been associated with low vitamin D levels, and so has treatment with efavirenz.

Many patients wait until after becoming infected with HIV to seek treatment.